| Dr Emmett David Ratigan, MD | |
|
3550 Lutheran Pkwy, Bldg 10 Suite 200, Wheat Ridge, CO 80033-6017 | |
| (720) 536-2100 | |
| (720) 536-2090 |
| Full Name | Dr Emmett David Ratigan |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 16 Years |
| Location | 3550 Lutheran Pkwy, Wheat Ridge, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003079583 | NPI | - | NPPES |
| 411559YVBJ | Other | CO | PTAN |
| 55407251 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 54717 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mesa County Dialysis (dva) | Grand junction, CO | Dialysis facility |
| Grand Junction Dialysis Center (dva) | Grand junction, CO | Dialysis facility |
| Black Canyon Dialysis (dva) | Montrose, CO | Dialysis facility |
| St Marys Medical Center | Grand junction, CO | Hospital |
| Montrose Memorial Hospital | Montrose, CO | Hospital |
| Delta County Memorial Hospital | Delta, CO | Hospital |
| Memorial Hospital, The | Craig, CO | Hospital |
| Community Hospital | Grand junction, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Scl Health Medical Group - Grand Junction Llc | 3779707856 | 207 |
News Archive
PuraMed BioScience, announced today that a clinical study of LipiGesic M has been completed. The study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic™ M for the treatment of acute migraine attacks. The next steps include completion of the manuscript, submission for publication in a peer-reviewed medical journal and actual publication. In an effort to maximize the potential for publication, an embargo has been placed on the disclosure of any of the results of this study.
The drug rimonabant was developed as a treatment for obesity and its myriad of serious health consequences. Despite having its desired effects on weight, which it decreased, and on levels of glucose and fats in the blood, rimonabant was never approved for use in the US because of serious neurological side effects including depression and anxiety. Now, a team of researchers, led by George Kunos, at the National Institutes of Health, Bethesda, and Alexandros Makriyannis, at Northeastern University, Boston, have developed a drug that has the same positive effects in mice on levels of glucose and fats in the blood as rimonabant but none of the neurological side effects.
A global recruitment drive to bring 20 of the world's best cancer experts and their teams to Manchester, in the United Kingdom, is now underway.
StemCells, Inc. announced today that is has received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to initiate a Phase I/II clinical trial in Switzerland of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in chronic spinal cord injury. The trial is designed to assess both safety and preliminary efficacy in patients with varying degrees of paralysis who are three to 12 months post-injury, and will progressively enroll patients based upon the severity of injury.
Individuals who experienced an out-of-hospital cardiac arrest in neighborhoods with higher percentages of black residents had lower rates of bystander CPR and defibrillator use and were less likely to survive compared to patients who experienced an OHCA in predominantly white neighborhoods, according to a study published by JAMA Cardiology.
› Verified 9 days ago
| Entity Name | Scl Health Medical Group - Grand Junction Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356765556 PECOS PAC ID: 3779707856 Enrollment ID: O20140611000363 |
News Archive
PuraMed BioScience, announced today that a clinical study of LipiGesic M has been completed. The study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic™ M for the treatment of acute migraine attacks. The next steps include completion of the manuscript, submission for publication in a peer-reviewed medical journal and actual publication. In an effort to maximize the potential for publication, an embargo has been placed on the disclosure of any of the results of this study.
The drug rimonabant was developed as a treatment for obesity and its myriad of serious health consequences. Despite having its desired effects on weight, which it decreased, and on levels of glucose and fats in the blood, rimonabant was never approved for use in the US because of serious neurological side effects including depression and anxiety. Now, a team of researchers, led by George Kunos, at the National Institutes of Health, Bethesda, and Alexandros Makriyannis, at Northeastern University, Boston, have developed a drug that has the same positive effects in mice on levels of glucose and fats in the blood as rimonabant but none of the neurological side effects.
A global recruitment drive to bring 20 of the world's best cancer experts and their teams to Manchester, in the United Kingdom, is now underway.
StemCells, Inc. announced today that is has received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to initiate a Phase I/II clinical trial in Switzerland of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in chronic spinal cord injury. The trial is designed to assess both safety and preliminary efficacy in patients with varying degrees of paralysis who are three to 12 months post-injury, and will progressively enroll patients based upon the severity of injury.
Individuals who experienced an out-of-hospital cardiac arrest in neighborhoods with higher percentages of black residents had lower rates of bystander CPR and defibrillator use and were less likely to survive compared to patients who experienced an OHCA in predominantly white neighborhoods, according to a study published by JAMA Cardiology.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Emmett David Ratigan, MD 130 Rampart Way, Suite 300b, Denver, CO 80230-6440 Ph: (303) 327-4700 | Dr Emmett David Ratigan, MD 3550 Lutheran Pkwy, Bldg 10 Suite 200, Wheat Ridge, CO 80033-6017 Ph: (720) 536-2100 |
News Archive
PuraMed BioScience, announced today that a clinical study of LipiGesic M has been completed. The study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic™ M for the treatment of acute migraine attacks. The next steps include completion of the manuscript, submission for publication in a peer-reviewed medical journal and actual publication. In an effort to maximize the potential for publication, an embargo has been placed on the disclosure of any of the results of this study.
The drug rimonabant was developed as a treatment for obesity and its myriad of serious health consequences. Despite having its desired effects on weight, which it decreased, and on levels of glucose and fats in the blood, rimonabant was never approved for use in the US because of serious neurological side effects including depression and anxiety. Now, a team of researchers, led by George Kunos, at the National Institutes of Health, Bethesda, and Alexandros Makriyannis, at Northeastern University, Boston, have developed a drug that has the same positive effects in mice on levels of glucose and fats in the blood as rimonabant but none of the neurological side effects.
A global recruitment drive to bring 20 of the world's best cancer experts and their teams to Manchester, in the United Kingdom, is now underway.
StemCells, Inc. announced today that is has received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to initiate a Phase I/II clinical trial in Switzerland of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in chronic spinal cord injury. The trial is designed to assess both safety and preliminary efficacy in patients with varying degrees of paralysis who are three to 12 months post-injury, and will progressively enroll patients based upon the severity of injury.
Individuals who experienced an out-of-hospital cardiac arrest in neighborhoods with higher percentages of black residents had lower rates of bystander CPR and defibrillator use and were less likely to survive compared to patients who experienced an OHCA in predominantly white neighborhoods, according to a study published by JAMA Cardiology.
› Verified 9 days ago
Mr. Ivan Benjamin Geller, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3885 Upham St, 100, Wheat Ridge, CO 80033 Phone: 303-742-0108 Fax: 303-742-0690 | |
Dr. Scott R Valent, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3655 Lutheran Pkwy, Suite #201, Wheat Ridge, CO 80033 Phone: 303-603-9800 | |
Carl Robert Dahl, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 8550 W 38th Ave Ste 300, Wheat Ridge, CO 80033 Phone: 303-463-3900 Fax: 303-463-3999 | |
Jennifer Ruth Pula, MD Nephrology Medicare: Medicare Enrolled Practice Location: 7821 W 38th Ave, Wheat Ridge, CO 80033 Phone: 303-422-2343 Fax: 303-422-8291 | |
Larry A Schafer, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 3655 Lutheran Pkwy, Suite 406, Wheat Ridge, CO 80033 Phone: 303-403-7333 Fax: 303-403-7335 | |
Norman K Fujita, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 3885 Upham St, Ste 200, Wheat Ridge, CO 80033 Phone: 303-425-9245 Fax: 303-425-1378 |